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Abstract
The ribosome-inhibiting toxin ricin binds exposed β1→4 linked galactosyls on 
multiple glycolipids and glycoproteins on the cell surface of most eukaryotic cells.
After endocytosis, internal cell trafficking is promiscuous, with only a small
proportion of ricin proceeding down a productive (cytotoxic) trafficking route to the
endoplasmic reticulum (ER). Here, the catalytic ricin A chain traverses the membrane
to inactivate the cytosolic ribosomes, which can be monitored by measuring reduction
in protein biosynthetic capacity or cell viability. Whilst some markers have been
discovered for the productive pathway, many molecular details are lacking. To
identify a more comprehensive set of requirements for ricin intoxication we have
developed an RNAi screen in Drosophila S2 cells, screening in parallel the effects of
individual RNAi treatments alone and when combined with a ricin challenge. Initial
screening of 806 gene knockdowns has revealed a number of candidates for both
productive and non-productive ricin trafficking including proteins required for
transport to the Golgi, plus potential toxin interactors within the ER and cytosol.
Keywords: Ricin, RNAi, S2 cells, screen, PDI, ERAD
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INTRODUCTION
The plant toxin ricin binds exposed cell-surface β1→4-linked galactosyls on surface 
components of mammalian cells via its B chain (RTB), entering the cells when these
components are endocytosed. A small proportion of endocytosed ricin traffics to the
endoplasmic reticulum (ER)1. Here the toxic A chain (RTA) is released from RTB by
protein disulphide isomerise (PDI)2, exposing a C-terminal hydrophobic patch on
RTA which interacts with the ER membrane3. Subsequently, RTA crosses (dislocates)
the ER membrane, entering the cytosol where it gains a catalytic conformation, aided
by molecular chaperones4. It then specifically depurinates a position in large
ribosomal subunit 28S rRNA5, resulting in loss of protein synthesis ability and
ultimately, cell death.
Overall knowledge of the intoxication pathway remains sparse. For example, ricin
may traffic through the Golgi stack6, but if so, it is not via known routes7. A likely
reason is ricin’s promiscuous surface binding which promotes multiple pathways to
the ER lumen. To gain further insight into ER events, we expressed RTA in the ER
lumen of Saccharomyces cerevisiae8, from where it dislocates. Dislocation requires
engagement with COPII-interacting p24 proteins, leading to Golgi trafficking and
subsequent ER return. RTA then utilises the integral membrane HRD ubiquitylation
complex of the ERAD (ER associated protein degradation) machinery that clears the
ER of misfolded proteins, targeting them to the cytosolic proteasomes for destruction.
However, RTA dislocates independently of ubiquitylation. Dislocated RTA then
avoids the proteasomal core and the final destructive steps of ERAD8.
Whilst this provides clues to RTA dislocation in mammalian cells, there are
significant differences between yeast and mammalian systems: for example, yeast
lacks the ER folding sensor UDP-glucose glycoprotein glucosyltransferase.
Furthermore, since yeast lacks β1,4 galactosyltransferases, it does not express ricin 
receptors, so cannot be probed for trafficking requirements that lie upstream of the ER
dislocation step. We therefore examined a genetically tractable higher eukaryote and
describe here the establishment of an RNAi screen of Drosophila S2 cells to probe for
all the requirements of ricin intoxication.
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MATERIALS AND METHODS
RNAi library construction
The Expression ArrestTM RNAi library releases 1.0 and 2.0 were purchased as dsDNA
templates in 96 well format (Open Biosystems)9. T7 polymerase was generated and
purified as previously described10. In vitro transcription reactions were performed in a
20 µl volume reaction with 3 µg DNA template, 5 mM rNTPs, 0.015 U.µl-1 yeast
inorganic pyrophosphatase (Sigma) and 0.2 U.µl-1 RNasin in a transcription buffer
(30 mM HEPES (pH7.8), 100mM Potassium Glutamate, 15 mM Magnesium acetate,
25 mM EDTA, 1 mM DTT). Activity of T7 polymerase was assessed using these
conditions and an optimal concentration per reaction employed for the library
synthesis. Reactions were incubated at 37oC for 4h. RNAi was then diluted 5x by the
addition of DEPC treated H2O. Yield was assessed by agarose gel electrophoresis.
Growth of S2 cells and cytotoxicity assays
S2 cells were maintained in Drosophila-SFM (Invitrogen) containing 18 mM
glutamine (Sigma), in rotating flasks (150 rpm, 28ºC). For cytotoxicity experiments,
cells were seeded into 96-well plates (15,000 cells/well) and grown (3d) and a range
of concentrations of ricin were added. After 24h, cell viability was assayed using
MTS reagent (Promega) and a Mithras LB940 multimode reader (Berthold
Technologies, Bad Wildbad, Germany). For RNAi screening experiments, cells were
seeded into pairs of wells, one containing specific dsRNAi (750 ng/well) and the other
an equivalent volume of water. After 3d, ricin was applied and cell viability was
measured.
Western Blot
Cells were seeded (375,000 cells/well) into 2 wells of a 6-well plate, one containing
specific RNAi targeting torp4a and the other an equivalent volume of water, and
grown for 3d. After gentle centrifugation (100 x g, 5 min), extracts were taken by
resuspending the cell pellets in 0.5 ml cold 10 mM Tris-HCl pH 7.5, 50 mM NaCl,
1% Triton X-100 containing protease inhibitor cocktail (Roche). Cell debris was
removed (10,000 x g, 1 min) and protein concentrations of the soluble extracts were
determined by colorimetric assay (Bio-Rad). Samples (10 μg) were separated by SDS-
PAGE and immunoblotted. Torp4a protein was revealed by serial probing with
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Rabbit anti-torp4a antibodies and peroxidise-conjugated anti-Rabbit antibodies
followed by ECL (GE Healthcare) development.
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RESULTS AND DISCUSSION
Adult Drosophila and S2 cells are sensitive to ricin
Fruit flies might be sensitive to ricin challenge since they express β1,4-
galactosyltransferases and their ribosomes are sensitive to RTA11. Isogenised wild
type Canton-S flies were starved (8h) to force a feeding response and were then fed
once with 1% sucrose (controls) or with 1% sucrose containing ricin, followed by a
daily maintenance diet of 1% sucrose. Drosophila show dose-dependent sensitivity to
ricin; most died 4d after an initial toxin feed of 4 μg.ml-1 ricin (Fig. 1A). By day 5 all
surviving flies fed with this dose showed uncoordinated movements; none recovered
from CO2 anaesthesia.
Drosophila S2 cells are also sensitive to a 24h challenge with ricin (Fig. 1B).
Addition of galactose during ricin challenge gave a dose-dependent protective effect
(Fig. 1C). Thus, intoxication of fly cells depends upon galactose binding as it does in
mammalian cells.
Establishing screening conditions
When S2 cells seeded at 15,000 cells per well in 96-well plates were grown for 4d,
cells in the outer wells of a plate grew more slowly than those in the central wells (Fig.
2A). Cells were therefore grown in the central wells only, filling the outer wells with
sterile water, resulting in optimal uniform growth.
A number of genes were selected to test RNAi conditions, along with ‘scrambled’
RNAi generated from a random arrangement of nucleotides from the sequence
encoding human syntaxin 16. Cells grown (3d) in the presence of dsRNA were treated
(24h) with a range of ricin concentrations. Golgi Tango7 RNAi did not alter the
response to ricin challenge (Fig. 2B): similarly dsRNAs directed against the ER
ribophorin, the cytosolic TER94 and ‘scrambled’ were ineffective (not shown). When
assays were performed without ricin challenge, some RNAi treatments had clear
growth effects (Fig. 2C), showing that for each RNAi knockdown screened with ricin
there should be a coeval control lacking ricin.
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To determine the screening concentration of ricin we treated cells with increasing
doses of ricin (Fig. 3) and modelled the effects of RNAi that would provide 2-, 5- and
10-fold protection (P) or sensitisation (S).  At a dose of 1 μg.ml-1 ricin, protective
RNAi effects of 2-fold or less would not be measurable, whereas after treatment with
62.5 ng.ml-1 ricin, sensitising RNAi effects would be most easily measured. We
chose 0.25 μg.ml-1 ricin for screening, biasing expected results towards protective
effects of 2-fold or more whilst still being able to recognise sensitising effects.
Preliminary screening of a library of individual RNAi molecules
Cells were grown in pairs of wells, both containing the same specific RNAi. One of
the pair was then treated with ricin, and subsequent viability was measured. Screening
plates also contained 6 control wells without RNAi treatment and a further 6 without
RNAi treatment subsequently challenged with ricin. Values from control wells on
each plate were used to determine a Z’-factor12. Plates that generated a Z’-factor of
greater than 0.5 were considered for further evaluation. Of 34 plates screened, only
one failed this test.
Initial screening of 96 randomly selected RNAi treatments is shown in Fig. 4A. Most
RNAi treatments gave low MTS signals. Results are displayed as a scatter, plotting
the relative effect of the combined RNAi/ricin treatment versus the relative effect of
RNAi alone (Fig. 4B). Completely protective RNAi treatments would be expected
along the line of unity connecting the (-) ‘cells alone’ control to the origin; ineffective
RNAi treatments should lie along the line connecting the (+) ‘cells plus ricin’ control
to the origin; protective RNAi treatments should accumulate in the segment between
these lines and sensitising RNAi treatments should collect in the segment between the
(+)-origin line and the abscissa. A few RNAi treatments sat outside these ranges with
ricin-treated samples growing more strongly than non-treated cells. These false
positives were from highly toxic RNAi treatments, reflecting difficulties in accurate
measurement of small MTS signals.
For each RNAi treatment pair, a standard z-score was determined - the
difference between treatment value (relative growth (%) after ricin treatment
compared to treatment with RNAi alone) and the mean value of all treatments divided
by the SD of all the treatment values. These are presented in a scatter versus relative
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growth after individual RNAi treatment (Fig. 4C). Practical considerations limit
accuracy of cytotoxicity curves where the RNAi-treated but non-ricin-treated controls
give an MTS signal of about a quarter of that of non-RNAi treated controls, allowing
us to reject 541 treatments (grey circles). Since RNAi treatment reduces rather than
abolishes expression of target genes, sensitivity changes to ricin might be small.
Furthermore, promiscuous binding/trafficking and multiple cytosolic interactions of
ricin lead to small changes after interfering with genes controlling toxicity1; 4. Rather
than use a z score threshold of 2 or 3, we therefore adopted an unusually low
threshold of 1, at the risk of increasing the false positive rate, to ensure capture of
such small changes. This led us to reject only those 182 treatments that lay between 0
and 1 SD from the mean score (white circles), leaving 45 RNAi treatments from an
initial screening population of 806 that reflect potentially sensitising and protective
RNAi treatments (black circles).
Confirmation of selected targets
Table 1 shows candidate ‘hits’ with human orthologs, ranked according to z-score. A
selection is marked in Figs. 4A, B, C and D. Supplementary Table S1 shows
candidates with no known human orthologs: most appear to have only arthropod
orthologs, and may be uninformative.
CG5809 encodes a PDI family member. In mammalian cells PDI reduces the
interchain disulphide bond between RTA and RTB2. We tested a different RNAi
against PDI (from the Sheffield RNAi Screening Facility, UK), confirming that
knockdown leads to protection against ricin in flies (Fig. 4D, upper panels).
CG6699 encodes the essential β’-COP subunit of the COPI coatomer complex which 
binds p24 cytosolic tails, allowing Golgi-to-ER transport of p24 proteins. Knockdown
by alternative RNAi confirmed reproducibility (Fig. 4D). CG31787 encodes a family
member of the fly p24 proteins, Type I transmembrane proteins with ill-defined roles
in Golgi-ER cargo transport13. Its yeast ortholog is Erp2p, which promotes transport
of RTA to the Golgi prior to recycling and dislocation8. Thus in fly cells, entry to the
Golgi from the ER may require a specific interaction with a p24 protein. The
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protective effects of RNAi against its expression and against expression of β’-COP in 
fly cells point to ER-Golgi cycling of RTA as a common feature of ricin intoxication.
The cytosolic fate of RTA is controlled by ubiquitin signals4. To test reproducibility
for sensitising RNAi ‘hits’, two different RNAi molecules against the low z-score
ubiquitin ligase-encoding archipelago (‘arch’, Fig. 4B), were compared (Fig. 4D,
lower panels). Both sensitised cells slightly to ricin. Examining the remaining
sensitising ‘hits’ revealed CG3024 (torp4a, an AAA-ATPase with a role in protein
folding in the ER lumen, Fig. 4B) as a presumptive ER modulator of ricin cytotoxicity.
Substantial torp4a knockdown gave only a modest (1.4 fold) sensitising effect (Fig.
4E), a minor effect consistent with low confidence in designating this a ‘hit’ from its
z-score position in Fig. 4C.
We have designed and performed a preliminary screen of approximately 6% of D.
melanogaster genes by RNAi knockdown, controlling in parallel for the effects of
RNAi alone. If our screen had tested only specific RNAi treatment with subsequent
ricin challenge, then from the first 96 RNAi treatments in Fig. 4A, some of the false
positives and only RNAi against the p24-encoding CG31787 would have been
identified as potentially protective, since these are the sole examples that gave a signal
greater than that of ricin-treated control cells. The growth inhibitory effects of RNAi
treatments against PDI and β’-COP would have led to the erroneous interpretation 
that reduced levels of these lead to ricin sensitivity. Indeed, the majority of RNAi
treatments would be deemed to be highly sensitising, giving signals substantially
lower than ricin-treated controls. A similar strategy that included testing the effects of
gene depletion alone14 underscores the need for inclusion of such a counter screen,
which broadens the dynamic range and allows us to identify false positives more
easily, thus improving the ability to identify likely candidates for genes involved in
the ricin intoxication process.
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Table 1. Candidate RNAi treatments with human orthologs that influence ricin
toxicity. Bold type indicates genes tested with two different RNAi molecules.
Target
gene
name Human ortholog Candidate role
z>3
CG8428 spinster spinster homolog 1 endocytosis
3>z>2
CG11184 Upf3 UPF3 regulator of
nonsense transcripts
homolog B (yeast)
gene silencing by miRNA
CG30429 none MORN repeat
containing 3
not known
CG10302 bicoid stability
factor
leucine-rich PPR-motif
containing
mRNA 3'-UTR binding
CG30338 none RWD domain
containing 2B
not known
CG31683 none phospholipase A2,
group XV
phospholipase
CG10078 Phosphoribosyl
amidotransferase 2
phosphoribosyl
pyrophosphate
amidotransferase
nucleoside metabolic process
CG5809 CaBP1 protein disulfide
isomerase family A,
member 6
reduction of ricin intra-
chain disulphide
CG31787 none ERP2 (yeast) ER to Golgi transport
CG3570 none UPF0532 protein
C7orf60
not known
CG6699 β'-coatomer 
protein
coatomer protein
complex, subunit beta
2 (beta prime)
ER-to-Golgi transport
CG8726 none PX domain containing
serine/threonine kinase
protein kinase
CG13708 none leucine rich repeat
containing 49
not known
-2<z<-1
CG3024 Torp4a torsin family 1,
member A (torsin A)
chaperone mediated protein
folding
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CG18654 none diacylglycerol kinase,
beta 90kDa
diacylglycerol kinase
CG5189 none roadblock domain
containing 3; Rab25
Golgi apparatus; endosome?
CG2173 Rs1 DEAD (Asp-Glu-Ala-
Asp) box polypeptide
27
RNA helicase; ribosome
biogenesis
CG3766 scattered vacuolar protein sorting
54 homolog
Endosome/Golgi transport
and sorting
CG33008 none transmembrane
protease, serine 4
serine-type endopeptidase
CG14396 Ret oncogene ret proto-oncogene signal transduction
CG5403 retained AT rich interactive
domain 3A (BRIGHT-
like)
transcription activator
CG15010 archipelago F-box and WD repeat
domain containing 7
ubiquitin-protein ligase
-3<z<-2
CG4046 Ribosomal protein
S16
ribosomal protein S16 structural constituent of
ribosome
CG11079 none 5,10-
methenyltetrahydro-
folate synthetase (5-
formyltetrahydrofolate
cyclo-ligase)
unknown
CG3029 orange adaptor-related protein
complex 3, sigma 2
subunit
intracellular protein transport
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Figure legends
Figure 1. Flies and S2 cells are sensitive to ricin. A). Starved adult flies were fed
with one meal of ricin at a range of concentrations in 1% sucrose, then fed daily with
a maintenance diet of 1% sucrose, and scored for survival. B). Dose response of S2
cells to a 24h exposure to a range of concentrations of ricin. C). Dose responses of S2
cells to a 24h exposure to a range of concentrations of ricin in the presence of
increasing concentrations of galactose.
Figure 2. Establishing screening conditions. A). Mean viabilities of cells grown on
the outer wells (outer, n = 36), remaining wells (inner, n = 60) or in the inner wells (n
= 60) of a plate whose outer wells were occupied with water (inner plus moat). Bars,
+/- 1 S.D. B). S2 cells were grown for 3d in the presence or absence of RNAi against
Tango7 and then treated for 24h with a range of concentrations of ricin prior to MTS
assay. C). Relative MTS signals of S2 cells treated with RNAi only.
Figure 3. Modelling the screen to determine ricin dose. Upper: S2 cells were
treated with a range of ricin concentrations and viability was measured by MTS assay,
generating a cytotoxicity curve (open circles). This curve was then shifted to the right
or the left to model likely results from 2-, 5- or 10-fold shifts in sensitivity (2XS, 5XS
and 10XS sensitising shifts: 2XP, 5XP and 10XP protective shifts). Lower: vertical
slices (dotted lines, upper panel) were used to model expected results of treating with
a range of concentrations of ricin. Arrows, magnitude of maximal protective (P) or
sensitising (S) effects.
Figure 4. Screening results. A). Left panel; MTS signals from initial screening of 96
RNAi treatments are displayed as pairs of bars (white, RNAi treatment alone; black,
RNAi treatment with subsequent ricin challenge). A number of candidate hits are
highlighted (arrows). Right panel: corresponding ricin-treated controls (no RNAi
treatment). B). Signals from A plotted in scatter format, defining the sectors into
which protective and sensitising hits are likely to fall. (-), cells alone; (+) cells treated
with ricin. C). Standard z-scores plotted versus relative growth of RNAi treated cells
for all 768 RNAi treatments tested. Grey circles: treatments rejected because the
RNAi signal alone was 25% or less that of non-RNAi-treated cells. White circles:
treatments rejected that lie within 1 SD from the mean value. Black circles: 45
remaining candidate treatments that may influence ricin cytotoxicity. D). Testing
alternative RNAi treatments: upper panels, RNAi treatments against PDI and β’-COP 
taken from B (RNAi 1, left) and from different RNAi treatments targeted against the
same genes (RNAi 2, right); lower panels, RNAi 1 (left panel) from B against
archipelago (arch) and an alternative RNAi 2 against the same gene (right panel). E).
Upper panel: cell extracts (10μg) of S2 cells treated or not (ctl) with torp4a RNAi 
were electrophoresed, immunoblotted and probed for torp4a protein. *, cross-reacting
protein. Approximate migration of size markers are shown on the left. Lower graph:
S2 cells treated or not with torp4a RNAi were subsequently treated with ricin and
viabilities were determined by MTS assay.
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Supplementary Table S1: Candidate RNAi treatments with no obvious human
orthologs
Target
gene
name Potential role
2>z>1
CG18659 none not known
CG17064 mars regulation of mitotic cell cycle
CG9858 cricklet carboxylesterase
CG30340 none G-protein coupled receptor
CG33503 Cyp12d1-d cytochrome P450
CG32249 none signal transducer
CG32335 none hydrolase activity, acting on ester bonds
CG8652 UDP-glycosyl-
transferase 37c1
glucuronosyltransferase
-2<z<-1
CG11163 none cation transport
CG14746 PGRP-SC1a innate immune response
CG5781 none not known
CG30491 none short-chain dehydrogenases/reductases family (SDR)
CG30090 none serine-type endopeptidase
CG10972 pickpocket 12 sodium channel
CG33461 none serine-type endopeptidase
CG30082 none not known
CG30268 none not known
CG4302 none glucuronosyltransferase
-3<z<-2
CG32245 none not known
CG3215 none glycerol-3-phosphate dehydrogenase




